Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nuvilex Investors Should Read Between the Lines as Company Attracts World Renowned Oncologist
NEW YORK, NY--(Marketwired - Apr 3, 2014) - That loud noise you hear coming from Nuvilex, Inc. (OTCQB: NVLX) this week is the collective excitement of many investors after the company stated it would be working with Translational Drug Development or TD2 and Dr. Daniel Von Hoff, the world's leading figure in pancreatic cancer, to develop its pancreatic cancer and other treatments utilizing Cell-in-a-Box® technology. Quite honestly Nuvilex may have just announced what might be one of the biggest stories in the biotechnology sector in all of 2014, and investors may not even realize it yet.
Nuvilex's announcement this week was filled with a number of monumental headlines, so here are the major takeaways from the news:
Translational Drug Development or TD2 will conduct preclinical and clinical studies for Nuvilex that seem aimed at the overall management of pancreatic cancer (further explanation below)
Dr. Daniel Von Hoff who just led NASDAQ's Celgene to FDA approval for its advanced inoperable pancreatic cancer treatment will now play a pivotal role in these studies done for Nuvilex at TD2
Nuvilex now has access to TD2's Pancreatic Cancer Research Team (PCRT) which consists of 65 Oncology Clinicians, Surgeons and Researchers who are member-investigators of the PCRT and who represent 45 clinical research sites worldwide
These are amazing headlines for any biotechnology firm, but for Nuvilex and its investors they represent a blockbuster achievement. The company has attracted world renowned oncologist Dr. Daniel Von Hoff, and that is no small feat given he's likely extremely selective about the projects he works with in pancreatic cancer, a field he's basically been writing the textbook in for years.
But, let's pay close attention to this week's press release for what it said and didn't say. At Stock Market Media Group, a full service investment relations firm focused on research and content development, we surmise the release is actually bigger than first thought. Here's what the company did say.
"TD2 will conduct preclinical and clinical studies in support of the development of Nuvilex's pancreatic cancer and other treatments utilizing Cell-in-a-Box technology."
We first thought the company was naming its Contract Research Organization (CRO), but at second glance it doesn't seem to be saying that at all. If that were the case, why would the company say "in support of the development of Nuvilex's pancreatic cancer and other treatments"? It is the use of "other treatments" that leads us to believe there is something even bigger going on here.
Then we took a longer look at Dr. Von Hoff's quote from the release:
"The Nuvilex team presents us with a new tool to employ against the symptoms and invasive properties of this very challenging cancer," said Daniel D. Von Hoff, M.D., Chief Development Officer of TD2. "Our Pancreatic Cancer Research Team (PCRT) colleagues are enthusiastic to begin clinical trials with this approach."
From this quote, we don't see words like survival rate, or median survival time, so we think Dr. Von Hoff and TD2 feel like Nuvilex has a treatment that can do more than first thought from the results of two independent Phase II clinical trials. It appears that when Dr. Von Hoff says "a new tool to employ against the symptoms and invasive properties," he may have other ideas that make Nuvilex's pancreatic cancer treatment an even broader remedy than even Nuvilex or Austrianova imagined.
What is clear is that Nuvilex is attracting some of the biggest names in cancer treatment development. Nuvilex's news is as good as it gets for a biotech with hopes of furthering a pancreatic cancer treatment, and investors couldn't have asked for a more impressive group to support the development of the company's treatment.
Dr. Daniel Von Hoff along with his team at TD2 have been shaping the path of cancer drugs at an alarming rate. With Dr. Von Hoff, Nuvilex gets a man who has been called the "voice of pancreatic cancer," and yes, he's the very same Dr. Daniel Von Hoff who just led Celgene to FDA approval with its drug Abraxane® plus gemcitabine, and the same Dr. Von Hoff who began Eli Lilly's clinical trials with Gemzar® (gemcitabine) both for advanced inoperable pancreatic cancer, and both became the "gold standard" for the disease.
TD2 is a world-class drug development service, specializing in getting the newest and best oncology treatments to cancer patients as quickly as possible. TD2 calls itself The Precision Oncology CRO™ and uses the slogan "Your Drug's Journey Begins Here." TD2 has managed and conducted more than 60 early-mid phase clinical studies and has worked with more than 350 biotech and pharmaceutical companies worldwide, so its interest in Nuvilex is great news for the Maryland biotech's future.
And, when a leading figure in pancreatic cancer, does in fact, choose to work with Nuvilex, he must feel the company's treatment can have an impact on the overall management of a disease that he's played a pivotal role in fighting against for many years now.
http://finance.yahoo.com/news/nuvilex-investors-read-between-lines-130000508.html
bull
styl....sorry you got offended but the only thing I was referring to about DD came out of your own wrong statements...
"NOW, in reply to dr. VON HOFF remark.............this is not NEW NEWS.......we already anounced that he would be an advisor for NUVILEX and we patted ourselves on the back last month about it.............Von HOFF like any doctor in his field will take a paycheck to be an advisor for a "promising" new "tool" as Von HOFF called it....to further cancer research.
So why all suprised as if its new news that they selected his CRO? wouldnt that have been the obvious next move? that still doesnt mean he works for nuvilex......its a great choice to do that....but........he is paid for his services......he didnt ask to join the nuvilex board of directors ....and says a general statement "we are excited to be working.......".....as expected by any work related press release. "
saying we already announced and patted ourselves on the back....saying he is an advisor....and saying he is on their board of directors...all wrong....
bull
while I agree with both of you.....I also think as a long you should not write things that uneducated investors might take to heart or short sellers might use to scare..we know we have one of them....
and as uneducated investors I mean no disrespect...I just mean brand spanking new investors that do not know the ropes yet....young investors getting their feet wet....older investors who are getting their feet wet because they got sick of their wall street investor that did not trade their holdings and saw their retirement go down in flames....so they sent them hiking....older investors that don't know how to use the internet very well to do their own DD...
be conscious....and no offense anarmyofme...
bull
short sellers should cover in the morning....buys in at last minute on Form T....@ .3889
nice day for the longs...more to come...we broke our pattern and next leg up in progress....
bull
CHART is looking beautiful......all that crap at .38 was about covering a gap down LOL...uptrend since we broke out of the pennant....indicators all pointing in the right direction...couldn't be better for the next leg up
bull
ATTENTION: Nuvilex, Inc. Releases Industry-Changing News Today!!
Dr. Von Hoff is a member of the Pancreatic Cancer "Dream Team" and is world renowned for his contributions to pancreatic cancer research in addition to the development of new cancer drugs.
Having Dr. Von Hoff play a leading role in Nuvilex's clinical trials for advanced, inoperable pancreatic cancer... will almost guarantee FDA approval of it's Cell-in-a-Box® treatment for the disease.
Dr. Von Hoff started the development of Gemzar® (gemcitabine) for Eli Lilly... which became the "Gold Standard" single agent treatment for advanced pancreatic cancer and has made Eli Lilly many billions of dollars in profits.
Dr. Von Hoff then led Celgene and its drug Abraxane® to FDA approval as the new "Gold Standard" treatment for advanced pancreatic cancer when he not only lead those clinical trials, but got Abraxane® "Fast Tracked" through the approval process with the FDA.
bull
Nuvilex is a buy and hold stock....I invest in bio's and this is one of the best I have come across lately....buy and hold is where you will reap unbelievable profit...
bull
maybe you can get some of your questions answered after you go do your homework before you write about Nuvilex....
what does this mean? What are you talking about?.....
"NOW, in reply to dr. VON HOFF remark.............this is not NEW NEWS.......we already anounced that he would be an advisor for NUVILEX and we patted ourselves on the back last month about it.............Von HOFF like any doctor in his field will take a paycheck to be an advisor for a "promising" new "tool" as Von HOFF called it....to further cancer research."
you don't even know who Daniel D. Von Hoff, M.D., Chief Development Officer of TD2.
and as far as being on an advisory board....that was Brian Salmons, Ph.D., CEO and President of Nuvilex’s partner Austrianova....
you know the same company we own 14.5 % of....and he was appointed to our Scientific Advisory Board of our subsidiary Medical Marijuana Sciences, Inc......
bull
what broker would do that...Scottrade would never sell a mistake like that....they get me the best pps at the time I make a trade....
bull
Dr. Daniel D. Von Hoff, M.D......Why do u think he wants to work with Cell_in_a_Box...."Pancreatic cancer presents a unique challenge because it is addicted to another molecule, glutamine, rather than glucose. Cancers that use excess glutamine are often resistant to standard forms of chemotherapy, a key characteristic of pancreatic cancer."
bull
Chart..stock has been holding support of a low of .025 around 2/11 ....and now has held it and bounced off of .025 since 3/24...so it is building support there...
bulll
Stand Up to Cancer (SU2C) Dream Team Doctors Craig Thompson and Daniel Von Hoff
Stand Up To Cancer Scientific Summit 2014
Progress Report: Pancreatic Cancer Dream Team
instead of ordering other people to do your DD...why don't you go find transparent information and come back and let the investors in on it...you seem to be the only one on here that has not done DD...
bull
Nuvilex won't be at this pps for long....the news isn't even really out there yet about the CRO.....and any one short doesn't have a leg to stand on and the flippers...every mb has one....we have ours...will keep fipping and then trashing the stock...no way to get around people like that...
bull
you have got to be kidding me....this is great news for Nuvilex...
Dr. Daniel Von Hoff is going to lead the company's clinical trials.
The Developer of Celgene's Abraxane® & Eli Lilly's Gemzar® (gemcitabine) is now going to Lead Nuvilex's Pancreatic Cancer Trials.
The same developer who has turned into an FDA Approval Machine. As the World's Leading Expert on Pancreatic Cancer, the FDA seems to approve everything Dr. Von Hoff touches related to the disease!!
bull
Daniel D. Von Hoff, M.D., F.A.C.P.
At present, he and his colleagues are concentrating on the development of molecularly targeted therapies particularly for patients with advanced pancreatic cancer. Dr. Von Hoff has published more than 569 papers, 135 book chapters and over 1000 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care.
bull
Daniel D. Von Hoff, M.D.
Dr. Von Hoff and his colleagues have conducted early clinical investigations of most of the new agents that have been approved for cancer treatment in the United States in the last two decades, including gemcitabine, docetaxel, paclitaxel, topotecan, irinotecan, fludarabine, mitoxantrone, dexrazoxane, nab-paclitaxel, and multiple others.
bull
Nuvilex Selects Translational Drug Development (TD2) to Advance Treatment for Pancreatic Cancer
SILVER SPRING, Md., April 1, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has signed a Master Services Agreement with Translational Drug Development (TD2) pursuant to which TD2 will conduct preclinical and clinical studies in support of the development of Nuvilex's pancreatic cancer and other treatments utilizing Cell-in-a-Box(R) technology.
"The Nuvilex team presents us with a new tool to employ against the symptoms and invasive properties of this very challenging cancer," said Daniel D. Von Hoff, M.D., Chief Development Officer of TD2. "Our Pancreatic Cancer Research Team (PCRT) colleagues are enthusiastic to begin clinical trials with this approach."
The PCRT, an affiliate of TD2, has the explicit mission to organize and accelerate the clinical development of new agents for the treatment of patients with pancreatic cancer. The PCRT members include laboratory and clinical researchers in the U.S. and Western Europe who share the passion to bring new advances to patients with pancreatic cancer as rapidly as possible, providing the only coordinated effort in the world dedicated to rapidly translating research discoveries into new treatments and supportive care for pancreatic cancer patients exclusively. To date, the PCRT consists of approximately 65 Oncology Clinicians, Surgeons and Researchers who are member-investigators of the PCRT and who represent 45 clinical research sites.
In commenting on TD2's work with Nuvilex, Kenneth L. Waggoner, Chief Executive Officer and President of Nuvilex, stated, "We are honored that TD2 and Dr. Von Hoff will play a pivotal role in the development of our treatment for patients with advanced pancreatic cancer that combines the proprietary Cell-in-a-Box(R) live-cell encapsulation technology with the cancer drug ifosfamide. TD2 integrates world-class preclinical, clinical and regulatory expertise and provides unique drug development services aimed at minimizing the risk for its clients in the oncology drug development industry. In addition, access to the PCRT that is enabled by our association with TD2 will not only make Nuvilex's approach widely known, but should facilitate its development as we move forward. The sincere interest in our advanced pancreatic cancer treatment that has been shown by TD2 is particularly rewarding to all of us."
TD2 is a precision oncology Contract Research Organization (CRO) that provides innovative services for oncology-focused biopharmaceutical companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening diseases. TD2 has managed and conducted more than 60 early-mid phase clinical studies and has worked with more than 350 biotech and pharmaceutical companies worldwide.
TD2 has facilities for the preclinical and clinical testing of candidate cancer drugs and treatments, as well as expertise in regulatory affairs matters with agencies such as the FDA. TD2 has more than 200 established models of human cancers available for preclinical studies and develops comprehensive drug development plans for the most efficient pathway for successful clinical trials. In addition, TD2 has capabilities and expertise in all aspects related to the conduct and management of clinical trials. TD2's drug regulatory affairs capabilities include the preparation and maintenance of Investigational New Drug Applications (INDs) that are necessary prior to the initiation of clinical trials, support for obtaining "breakthrough" designations and "fast track, priority review and accelerated approval" filings for cancer drugs and treatments. The TD2 team has collective experience in filing more than 60 INDs in the U.S. alone. In countries outside the U.S., TD2 can provide filing and maintenance services for Clinical Trial Applications and Investigational Medicinal Product Dossiers.
About Nuvilex:
Nuvilex is a clinical-stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology, called Cell-in-a-Box(R). This unique technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. Nuvilex's treatment for pancreatic cancer involves the widely used anticancer prodrug, ifosfamide, together with encapsulated live cells that convert ifosfamide into its active or "cancer-killing" form.
About TD2:
In addition to what is set forth above about Translational Drug Development (TD2), TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory and clinical expertise, to customize clinical trial design and execution. TD2's suite of capabilities encourages the timely selection of patient populations most likely to benefit from a new agent and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments.
and who cares what he does....he has acted like a 6 yr old since he came on the mb....
and I'm sure we are all waiting with baited breath....
he didn't drag down the pps.....he is just one small peon....and the stock seems to be holding support above the .025 pps...so let's see what happens...
bull
Chart......do u guys realize that since we had our run up from 2/18 and starting forming our triangle...we have not closed below .312....so the support of .31 that I have been giving you has held for 6 weeks...
bull
everyone knows what you are trying to do...there is at least one on every message board on here...lol
so that is why he is here trashing xtrm...he is in such a pos stock.....lol
bull
really...then why are you spending so much of your time informing all of us about our investment in XTRM....all out of the goodness of your heart....quit the b.....does anyone believe any of what you say....be short ...be long....trade all u want....I get so tired of the bull....
thank you for your informative post....we all appreciate it
bull
a little advice for the taking....even if you are going to trade the stock....I don't...I'm holding long and adding....while you wait...do some really good DD on Nuvilex....and you will probably end up holding at least a core position and will be well paid for it....good luck
bull
Now is your time to buy....the stock is so squeezed in the apex right now...it WILL bust loose...and we have held support at .31 three times now......Triple Bottom....
keep
look guys...this is a long term hold....not a make a million in 6 months.....why don't we just wait and see what will happen with the trials...yes there is a 2b...but they could run them at the same time...Phase II/III Trial....we just don't know yet..regardless if you are looking for a quick million...go elsewhere..this is a bio..but keep in mind how far in the game they already are....a bio just starting R&D takes about 7-9 yrs sometimes and then the trials take another 9 or so yrs...we are so far ahead of the game acquiring Cell-in-a-Box like we did...but you need patience....
bull
they closed escrow.....
Wall Street PR
Can Nuvilex Inc (OTCMKTS:NVLX) Be The Difference?
Boston, MA 03/28/2014 (wallstreetpr) – For investors who want value, hunting for the most promising stocks is second nature. But sometimes you have so many options to consider that you can get overwhelmed. And this is why Nuvilex Inc (OTCMKTS:NVLX) takes the stage today. This company operates independently and also through subsidiaries which it owns wholly. Its line of products is development of treatment for cancer and diabetes. The company holds the worldwide right to live-cell encapsulation.
With growing excitement and opportunities in medical marijuana, the company has interest in the cannabis sectors, where it already has a business subsidiary.
Upcoming events and their impact
Talk about medical marijuana and Nuvilex Inc (OTCMKTS:NVLX) will be dispatching one of its executives to present at the upcoming medical cannabis unity conference in Washington, D.C. The company announced that Dr. Mark L. Rabe who is the current chair of the advisory board of its Medical Marijuana Sciences subsidiary will present at the April 5 – 7, event. Dr. Rabe, will issue a review of the history of medical use of cannabis and the constituents of pot which have biological values. Particular emphasis will be placed on the serious diseases which marijuana extracts can help in solving.
The company recently tapped Dr. Brian Salmons to the advisory board of its subsidiary, Medical Marijuana Sciences. All these are in efforts to ensure that top-notch brains and technologies are deployed to work in the promising medical cannabis industry, of course, with an eye on creating shareholder value.
Pancreatic cancer treatment
High on the agenda of Nuvilex Inc (OTCMKTS:NVLX)’s ongoing research and development activities is solving the riddles that are cancer and diabetes. And the company is making good of its global right to live-cell technology to bring to the market a ground breaking therapy for pancreatic cancer.
As the company takes its research and development of cancer therapies from success to success, investors are already flocking in with their dollars. And in a press release, the company recently announced receiving $27 million towards clinical trial of its pancreatic cancer drugs. The funds came from an institutional investors based in Chicago.
According to the company, with its drugs currently under clinical trials showing significant success, it is just a matter of time before they pull through with “gold standard” status, the kind that earned Eli Lilly and Co (NYSE:LLY) more than $10 million in milestone payments through its drug Gemzar.
Investor Takeaway
They say that the best way to play biotech stock is to exercise patience because patients are needed. Anyway, investors who have been patient with the progress with Nuvilex Inc (OTCMKTS:NVLX) are not far from smiling all the way to the bank now that milestones payments are expected to start coming in torrent.
bull
wow.....thanks.....we all must of missed that....appreciate it...how do you find all the things the uniformed owners of this stock miss....you are good at your job
bull
thanks for the heads up..I know everyone on here appreciates all your hard work....
bull
that is your comment......"Someone mentioned all the PRs were coming out of Temecula I think. Wow more red flags"....
that is where their offices are...quit trying to act like you are not a short....
bull
Nuvilex is an investment....and at these prices is a no-brainer...so the traders have their fun for a while...so what... we don't have to pay attention to them ...they repeat the same thing over and over...and at the end of the year they will eat their words and have no cred...nuvilex is both an investment and a trade...so is every other stock...so...I ignore...because they have no point
bull
Nuvilex is an investment.....you are just trading it for pennies...that was apparent on your last post when you made $40.00 off of your trade...I did not understand a word you just said but good luck in your next penny trade...I will be holding my investment for a long time....
bull
no they didn't read anything...they would rather speculate and cause fear and then wonder why their stock is going down...XTRM is a long hold....it will take time to develop....what did you guys think...they would close escrow on the land and miraculously the hemp would grow overnight...containers would appear and fencing and security would suddenly appear...grow up....
bull
what readers...go to your web page and do it there ...they pay you for that don't they....this is ihub...not your free enterprise...
there is no after hours in the pink or otc.....those trades are form T trades...they could be 1 trade...or 500 trades averaged together....they may be held all day and put in after hours on a form T....they could be buys they could be sells...
don't get excited about them...except where they add to the volume...we want volume and pps going up...
bull